Publications: Monitoring Change of PD-L1 Expression

• AACR 2026: Monitoring PD-L1 in Tumor Macrophage Fusion Cells in Blood Identifies High PD-L1 Checkpoint Inhibitor Responses in Metastatic Breast Cancer

• San Antonio Breast Cancer Symposium 2025: Monitoring Upregulation of PD-L1 in Cancer Associated Macrophage-Like Cells in Blood Predicts Clinical Outcomes in Metastatic Cancer Patients Treated with PD-L1 Immunotherapies

• San Antonio Breast Cancer Symposium 2025: Prolonged survival following PD-L1/PD-1 immune checkpoint inhibitor therapy after leronlimab induced PD-L1 upregulation on cancer-associated macrophage-like cells and circulating tumor cells in patients with metastatic or locally advanced triple-negative breast cancer

• ASCO 2025: Monitoring PD-L1 Expression in Cancer-Associated Macrophage-Like Cells as Predictor of Clinical Outcomes in Metastatic Cancer Patients Treated with PD-L1 Immunotherapies

• ESMO 2025: Long Term Survival with Leronlimab Treatment in Patients with MetastaticTriple-Negative Breast Cancer (mTNBC)

• AACR 2025: Monitoring PD-L1 Expression in Cancer Associated Macrophage-Like Cells in Blood predicts Clinical Outcomes in Metastatic Cancer Patients Treated with PD-L1 Immunotherapies

• SABCS 2024: PD-L1 Upregulation in Circulating Tumor Associated Cells Predicts for Clinical Outcomes in a Phase 1/2 Clinical Trial Using SV-BR-1-GM Vaccine with the Check Point Inhibitor Retifanlimab in Metastatic Breast Cancer Patients, an Interim Analysis

• Polyploid Giant Cancer Cells 2024: PD-L1 Expression on Circulating Tumor Associated Macrophage Polyploids Predicts Patient Outcomes in Metastatic Breast Cancer

• Immunology 2023:  PD-L1 expression on circulating antigen presenting macrophages in blood predicts PFS & OS in an array of metastatic cancer types treated with PD-L1/PD-1 immunotherapies

• Monitoring PD-L1 Expression on Circulating Tumor–Associated Cells in Recurrent Metastatic Non–Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy

  Jillian A. Moran, BA; Daniel L. Adams, BS; Martin J. Edelman, MD; Pablo Lopez, PhD; Jianzhong He, PhD; Yawei Qiao, PhD; Ting Xu, PhD; Zhongxing Liao, PhD; Kirby P. Gardner, MBS; Cha-Mei Tang, ScD; and Steven H. Lin, MD, PhD 2022 American Society of Clinical Oncology

• ASCO 2022: Monitoring PD-L1 Expression on Circulating Stromal Cells in Blood Predicts PFS and OS in Metastatic NSCLC Patients Treated with PD-L1/PD-1 Immunotherapy      

• ASCO 2021: Sequential Monitoring of PD-L1 on Circulating Stromal Cells in Blood Predicts PFS in NSCLC Patients Undergoing Immunotherapy after Definitive Chemoradiation

• EDRN 2021: Sequential Monitoring of PD-L1 on Circulating Stromal Cells Predicts Outcomes in Localized Unresectable Stage II NSCLC Treated with Immunotherapy after Definitive Chemoradiation

• AACR 2020: Expression of PD-L1 on Circulating Stromal Cells Predicts Immunotherapy Response in Unresectable Non-Small Cell Lung Carcinoma After Definitive Chemoradiotherapy

• ASCO 2020: Sequential Monitoring of Circulating Stromal Cells from Blood is Predictive of Progression in NSCLC Patients Undergoing Anti-PD-L1 Therapy after Definitive Chemoradiation Therapy

• AACR 2018: Real time monitoring of solid tumor progression by circulating stromal cells in early and late stage disease

• Sequential tracking of PD-L1 expression and RAD50 induction in circulating tumor and stromal cells of lung cancer patients undergoing radiotherapy

  Adams DL, Adams DK, He J, Kalhor N, Zhang M, Xu T, Gao H, Reuben JM, Qiao Y, Komaki R, Liao Z, Edelman MJ, Tang C-M, Lin SH, Clinical Cancer Research, Published Online First August 16, 2017 DOI: 10.1158/1078-0432.CCR-17-0802

• AACR 2016: Sequential tracking of PD-L1 expression and RAD50 induction in CTCs and circulating stromal cells of lung cancer patients during treatment with radiotherapy